Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY

Vibeke Strand, Namita Tundia, Alvin Wells, Maya H Buch, Sebastiao C Radominski, Heidi S Camp, Alan Friedman, Jessica L Suboticki, Kendall Dunlap, Debbie Goldschmidt, Martin Bergman, Vibeke Strand, Namita Tundia, Alvin Wells, Maya H Buch, Sebastiao C Radominski, Heidi S Camp, Alan Friedman, Jessica L Suboticki, Kendall Dunlap, Debbie Goldschmidt, Martin Bergman

Abstract

Objective: To evaluate the effect of upadacitinib (UPA) monotherapy vs MTX on patient-reported outcomes (PROs) in patients with RA who were MTX-naïve or who had an inadequate response to MTX (MTX-IR).

Methods: PROs from the SELECT-EARLY and SELECT-MONOTHERAPY randomized controlled trials were evaluated at Weeks 2 and 12/14. Patients were ≥18 years of age with RA symptoms for ≥6 weeks (SELECT-EARLY, MTX-naïve) or diagnosed RA for ≥3 months (SELECT-MONOTHERAPY, MTX-IR) and received UPA monotherapy (15 or 30 mg) or MTX. PROs included Patient Global Assessment of Disease Activity (PtGA), pain visual analogue scale, HAQ Disability Index (HAQ-DI), morning stiffness duration/severity, Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue (SELECT-EARLY), health-related quality of life (HRQOL) by the 36-iem Short Form Health Survey and Work Productivity and Activity Impairment (WPAI; SELECT-EARLY). Least square mean (LSM) changes and proportions of patients reporting improvements greater than or equal to the minimum clinically important differences and normative values were determined.

Results: In 945 MTX-naïve and 648 MTX-IR patients, UPA monotherapy (15 mg, 30 mg) vs MTX resulted in greater reported LSM changes from baseline at Weeks 12/14 in PtGA, pain, HAQ-DI, morning stiffness duration/severity, FACIT-F (SELECT-EARLY), HRQOL and WPAI (SELECT-EARLY). These changes were statistically significant with both doses of UPA vs MTX at Weeks 12/14 in both RCTs. Improvements were reported as early as week 2. Compared with MTX, more UPA-treated MTX-naïve and MTX-IR patients reported improvements greater than or equal to the minimum clinically important differences and scores greater than or equal to normative values.

Conclusion: Among MTX-naïve and MTX-IR patients with active RA, UPA monotherapy at 15 or 30 mg for 12/14 weeks resulted in statistically significant and clinically meaningful improvements in pain, physical function, morning stiffness, HRQOL and WPAI compared with MTX alone.

Clinical trial registration number: SELECT-EARLY (NCT02706873) and SELECT-MONOTHERAPY (NCT02706951) are registered with ClinicalTrials.gov.

Keywords: DMARDs; RA; inflammation; outcome measures; quality of life.

© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology.

Figures

Fig . 1
Fig. 1
Change in SF-36 domain over time relative to age- and gender-matched normative values (A) SF-36 domain scores at baseline and week 12 in MTX-naïve patients vs age- and gender-matched normative values. (B) SF-36 domain scores at baseline and week 14 in MTX-IR patients vs age- and gender-matched normative values. A/G, age/gender; BL, baseline; BP, bodily pain; GH, general health; MH, mental health; MTX-IR, inadequate response to MTX; PF, physical functioning; RE, role-emotional; RP, role-physical; SF, social functioning; SF-36, 36-Item Short Form Health Survey; UPA, upadacitinib; VT, vitality; Wk, week.
Fig . 2
Fig. 2
Patients reporting PRO score improvements greater than or equal to the MCID at week 12 or 14 (A) Percentage of MTX-naïve patients reporting PRO scores greater than or equal to the MCID at week 12. (B) Percentage of MTX-IR patients reporting PRO scores greater than or equal to the MCID at week 14. AM, morning; FACIT-F, Functional Assessment of Chronic Illness Therapy–Fatigue; HAQ-DI, Health Assessment Questionnaire Disability Index; MCID, minimum clinically important difference; MCS, Mental Component Summary; MTX-IR, inadequate response to MTX; NNT, number needed to treat; PCS, Physical Component Summary; PRO, patient-reported outcome; PtGA, Patient’s Global Assessment of Disease Activity; SF-36, 36-Item Short Form Health Survey; UPA, upadacitinib; VAS, visual analogue scale; WPAI, Work Productivity and Activity Impairment Questionnaire.
Fig . 3
Fig. 3
Patients reporting SF-36 domain score improvements greater than or equal to the MCID at week 12 or 14 (A) Percentage of MTX-naïve patients reporting SF-36 domain scores greater than or equal to the MCID at week 12. (B) Percentage of MTX-IR patients reporting SF-36 domain scores greater than or equal to the MCID at week 14. BP, bodily pain; GH, general health; MCID, minimum clinically important difference; MH, mental health; MTX-IR, inadequate response to MTX; NNT, number needed to treat; PF, physical functioning; RE, role-emotional; RP, role-physical; SF, social functioning; SF-36, 36-Item Short Form Health Survey; UPA, upadacitinib; VT, vitality.

References

    1. Radner H, Smolen JS, Aletaha D.. Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs. Arthritis Res Ther 2014;16:R56.
    1. Smolen JS, Aletaha D, McInnes IB.. Rheumatoid arthritis. Lancet 2016;388:2023–38.
    1. Strand V, Khanna D.. The impact of rheumatoid arthritis and treatment on patients’ lives. Clin Exp Rheumatol 2010;28(3 Suppl 59):S32–40.
    1. Taylor PC, Moore A, Vasilescu R, Alvir J, Tarallo M.. A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. Rheumatol Int 2016;36:685–95.
    1. Smolen JS, Landewe RBM, Bijlsma JWJ. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020;79:685–99.
    1. Singh JA, Saag KG, Bridges SL Jr. et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res 2016;68:1–25.
    1. Curtis JR, Bykerk VP, Aassi M, Schiff M.. Adherence and persistence with methotrexate in rheumatoid arthritis: a systematic review. J Rheumatol 2016;43:1997–2009.
    1. Curtis JR, Wallenstein G, Takiya L. et al. Patterns of methotrexate use and discontinuation in a U.S. rheumatoid arthritis registry. Arthritis Rheumatol 2017;69(Suppl):abstract 1815.
    1. Harrold L, Litman HJ, O’Brien J. et al. Methotrexate treatment patterns in advanced therapy-naive patients with rheumatoid arthritis: clinical characteristics and outcomes of patients in the Corrona registry. Ann Rheum Dis 2019;78:747–8.
    1. Parmentier JM, Voss J, Graff C. et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol 2018;2:23.
    1. RINVOQ (upadacitinib) [package insert]. Sligo, Ireland: AbbVie Ireland, 2019.
    1. European Medicines Agency. RINVOQ (upadacitinib): summary of product characteristics. (18 February 2020, date last accessed).
    1. van Vollenhoven R, Takeuchi T, Pangan A. et al. A phase 3, randomized, controlled trial comparing upadacitinib monotherapy to MTX monotherapy in MTX-naïve patients with active rheumatoid arthritis. Rheumatology 2019;58(Suppl 3):abstract 059.
    1. Smolen JS, Pangan AL, Emery P. et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet 2019;393:2303–11.
    1. Strand V, Pope J, Tundia N. et al. Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT. Arthritis Res Ther 2019;21:272.
    1. Strand V, Schiff M, Tundia N. et al. Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs. Arthritis Res Ther 2019;21:263.
    1. van Vollenhoven R, Takeuchi T, Pangan AL. et al. Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately to severely active rheumatoid arthritis (SELECT-EARLY): a randomized, double-blind, active-comparator, multi-center, multi-country trial. Arthritis Rheumatol 2020;72:1607–20.
    1. Bruce B, Fries JF.. The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol 2005;23(5 Suppl 39):S14–8.
    1. Orbai AM, Smith KC, Bartlett SJ, De Leon E, Bingham CO III.. “Stiffness has different meanings, I think, to everyone”: examining stiffness from the perspective of people living with rheumatoid arthritis. Arthritis Care Res 2014;66:1662–72.
    1. Ware JE Jr, Sherbourne CD.. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473–83.
    1. Busija L, Pausenberger E, Haines TP. et al. Adult measures of general health and health-related quality of life: Medical Outcomes Study Short Form 36-Item (SF-36) and Short Form 12-Item (SF-12) Health Surveys, Nottingham Health Profile (NHP), Sickness Impact Profile (SIP), Medical Outcomes Study Short Form 6D (SF-6D), Health Utilities Index Mark 3 (HUI3), Quality of Well-Being Scale (QWB), and Assessment of Quality of Life (AQoL). Arthritis Care Res 2011;63(Suppl 11):S383–412.
    1. Cella D, Yount S, Sorensen M. et al. Validation of the functional assessment of chronic illness therapy fatigue scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol 2005;32:811–9.
    1. Zhang W, Bansback N, Boonen A. et al. Validity of the work productivity and activity impairment questionnaire–general health version in patients with rheumatoid arthritis. Arthritis Res Ther 2010;12:R177.
    1. Kitchen H, Hansen BB, Abetz L, Hojberre L, Strandberg-Larsen M.. Patient-reported outcome measures for rheumatoid arthritis: minimal important differences review. Arthritis Rheumatol 2013;65:abstract 2268.
    1. Strand V, Boers M, Idzerda L. et al. It’s good to feel better but it’s better to feel good and even better to feel good as soon as possible for as long as possible. Response criteria and the importance of change at OMERACT 10. J Rheumatol 2011;38:1720–7.
    1. Fleischmann R, Weinblatt ME, Schiff M. et al. Patient-reported outcomes from a two-year head-to-head comparison of subcutaneous abatacept and adalimumab for rheumatoid arthritis. Arthritis Care Res 2016;68:907–13.
    1. Krishnan E, Sokka T, Hakkinen A, Hubert H, Hannonen P.. Normative values for the health assessment questionnaire disability index: benchmarking disability in the general population. Arthritis Rheumatol 2004;50:953–60.
    1. Kavanaugh A, Gladman DD, Edwards CJ. et al. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (104-week) improvement in fatigue in patients with psoriatic arthritis: pooled results from 3 phase III, randomized, controlled trials. Ann Rheum Dis 2016;75:1065–73.
    1. Strand V, Crawford B, Singh J. et al. Use of “spydergrams” to present and interpret SF-36 health-related quality of life data across rheumatic diseases. Ann Rheum Dis 2009;68:1800–4.
    1. Ara R, Brazier J.. Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (where patient level data are not available). Value Health 2008;11:1131–43.
    1. Ara R, Brazier J.. Predicting the short form-6D preference-based index using the eight mean short form-36 health dimension scores: estimating preference-based health-related utilities when patient level data are not available. Value Health 2009;12:346–53.
    1. van Tuyl LH, Sadlonova M, Hewlett S. et al. The patient perspective on absence of disease activity in rheumatoid arthritis: a survey to identify key domains of patient-perceived remission. Ann Rheum Dis 2017;76:855–61.
    1. Kirwan JR, Newman S, Tugwell PS. et al. Progress on incorporating the patient perspective in outcome assessment in rheumatology and the emergence of life impact measures at OMERACT 9. J Rheumatol 2009;36:2071–6.
    1. Minnock P, Kirwan J, Bresnihan B.. Fatigue is a reliable, sensitive and unique outcome measure in rheumatoid arthritis. Rheumatology 2009;48:1533–6.
    1. Strand V, Lee EB, Fleischmann R. et al. Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial. RMD Open 2016;2:e000308.
    1. Fleischmann R, Schiff M, van der Heijde D. et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol 2017;69:506–17.
    1. Schiff M, Takeuchi T, Fleischmann R. et al. Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Res Ther 2017;19:208.
    1. Strand V, Kremer J, Wallenstein G. et al. Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs. Arthritis Res Ther 2015;17:307.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel